Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback